Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Paul Ausick | Aug 9, 2016 at 8:40 AM EDT

Zika Threatens Florida’s $82 Billion Tourism Revenue

If the Zika virus should spread beyond its currently known location near Miami, it could threaten some of Florida's largest…

Jon C. Ogg | Aug 8, 2016 at 12:45 PM EDT

Why Credit Suisse Sees Merck and Bristol-Myers Gap Widening Further

Credit Suisse sees the Bristol-Myers Squibb gap with Merck getting even worse, even though it still has robust I-O franchise…

Paul Ausick | Aug 8, 2016 at 7:55 AM EDT

Why Allergan Earnings Aren’t Telling the Whole Story

Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.

Chris Lange | Aug 5, 2016 at 10:35 AM EDT

Why Bristol-Myers Failure Is a Huge Win for Merck

Bristol-Myers Squibb shares took a nosedive early Friday's following an update in its late-stage Checkmate trial. But Bristol-Myer's failure was…

Lee Jackson | Aug 5, 2016 at 10:20 AM EDT

Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick

A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in…

Douglas A. McIntyre | Aug 5, 2016 at 9:40 AM EDT

Zika Threatens Florida’s $67 Billion Tourism Industry

In Miami, spraying for Zika is in full swing. However, infection rates continue to rise, and the virus has begun…

Douglas A. McIntyre | Aug 5, 2016 at 9:35 AM EDT

Theranos Death Watch (Update)

There have been several developments since 24/7 Wall St. posted its Theranos Death Watch Continues story.

Lee Jackson | Aug 4, 2016 at 10:40 AM EDT

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that…

Chris Lange | Aug 3, 2016 at 12:50 PM EDT

What Expect From Teva Earnings

Teva Pharmaceutical Industries is scheduled to release its second-quarter financial results before the markets open on Thursday.

Lee Jackson | Aug 3, 2016 at 9:55 AM EDT

4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts

A new report from Wedbush focuses on upcoming catalysts for biotech stocks in the firm's coverage universe. These four have…

Jon C. Ogg | Aug 2, 2016 at 12:35 PM EDT

Why Advaxis Shares Could More Than Double, Even After the Amgen Deal

According to one analyst, Advaxis shares could still easily more than double, even after news broke that biotech giant Amgen…

Douglas A. McIntyre | Aug 2, 2016 at 9:20 AM EDT

Zika Response Spreads North and West in US

The presence of the Zika virus is not concentrated in Florida, although the state has more confirmed cases than any…

Chris Lange | Aug 2, 2016 at 9:05 AM EDT

Pfizer Earnings Fail to Impress Investors

When Pfizer reported its second-quarter financial results before the markets opened on Tuesday, investors initially did not appear impressed.

Paul Ausick | Aug 2, 2016 at 8:15 AM EDT

Zika Threatens Florida’s $67 Billion Tourism Revenue

On Monday, the CDC issued its first-ever travel warning for a destination inside the United States. The warning could pose…

Chris Lange | Aug 1, 2016 at 11:25 AM EDT

What to Expect From Pfizer Earnings

The upcoming earnings report will showcase what Pfizer has to offer for the second half of 2016, and potentially give…

1 … 199 200 201 202 203 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Zika Threatens Florida’s $82 Billion Tourism Revenue

Why Credit Suisse Sees Merck and Bristol-Myers Gap Widening Further

Why Allergan Earnings Aren’t Telling the Whole Story

Why Bristol-Myers Failure Is a Huge Win for Merck

Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick

Zika Threatens Florida’s $67 Billion Tourism Industry

Theranos Death Watch (Update)

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

What Expect From Teva Earnings

4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts

Why Advaxis Shares Could More Than Double, Even After the Amgen Deal

Zika Response Spreads North and West in US

Pfizer Earnings Fail to Impress Investors

Zika Threatens Florida’s $67 Billion Tourism Revenue

What to Expect From Pfizer Earnings

Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old’s Social Security, But It Can Raise Medicare Two Years Later

Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts

Dividend Safety Check: International Small-Cap Value ETFs (DISV, ISVL)

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old's Social Security, But It Can Raise Medicare Two Years Later

COLA Went Up in 2026, but Medicare Quietly Took $215 of It

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old’s Social Security, But It Can Raise Medicare Two Years Later

Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts

Health and Healthcare Articles

All Health and Healthcare Articles

Zika Threatens Florida’s $82 Billion Tourism Revenue

Why Credit Suisse Sees Merck and Bristol-Myers Gap Widening Further

Why Allergan Earnings Aren’t Telling the Whole Story

Why Bristol-Myers Failure Is a Huge Win for Merck

Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick

Zika Threatens Florida’s $67 Billion Tourism Industry

Theranos Death Watch (Update)

Merrill Lynch Says the Time to Put Money Into Biotech Is Now

What Expect From Teva Earnings

4 Biotech Stocks With Up to 300% Upside Potential and Upcoming Catalysts

Why Advaxis Shares Could More Than Double, Even After the Amgen Deal

Zika Response Spreads North and West in US

Pfizer Earnings Fail to Impress Investors

Zika Threatens Florida’s $67 Billion Tourism Revenue

What to Expect From Pfizer Earnings

Live Nasdaq Composite: Cautious Optimism Takes Hold as Chip Stocks Rebound and SpaceX IPO Nears

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old’s Social Security, But It Can Raise Medicare Two Years Later

Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts

Dividend Safety Check: International Small-Cap Value ETFs (DISV, ISVL)

Featured Reads

Earning $0 or $100,000 in Your Final Year Barely Moves a 66-Year-Old's Social Security, But It Can Raise Medicare Two Years Later

COLA Went Up in 2026, but Medicare Quietly Took $215 of It